Arcturus TherapeuticsARCT
About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Employees: 176
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 46
0.32% more ownership
Funds ownership: 98.05% [Q3] → 98.36% (+0.32%) [Q4]
1% less call options, than puts
Call options by funds: $2.94M | Put options by funds: $2.98M
11% less funds holding
Funds holding: 164 [Q3] → 146 (-18) [Q4]
26% less capital invested
Capital invested by funds: $615M [Q3] → $452M (-$163M) [Q4]
52% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 31
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Canaccord Genuity Whitney Ijem 23% 1-year accuracy 10 / 43 met price target | 567%upside $68 | Buy Maintained | 10 Mar 2025 |
HC Wainwright & Co. Ed Arce 36% 1-year accuracy 40 / 111 met price target | 488%upside $60 | Buy Maintained | 7 Mar 2025 |
Wells Fargo Yanan Zhu 11% 1-year accuracy 1 / 9 met price target | 390%upside $50 | Overweight Maintained | 7 Mar 2025 |
BTIG Thomas Shrader 0% 1-year accuracy 0 / 8 met price target | 302%upside $41 | Buy Initiated | 28 Jan 2025 |
Financial journalist opinion
Based on 4 articles about ARCT published over the past 30 days









